[CAS NO. 537-42-8] Pterostilbene

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [537-42-8]

Catalog

HY-N0828

Brand

MCE

CAS

537-42-8

DESCRIPTION [537-42-8]

Overview

MDL	MFCD00238710
Molecular Weight	256.30
Molecular Formula	C16H16O3
SMILES	OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium ^[1] . Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties ^[1] ^[4] . Pterostilbene blocks ROS production ^[3] , also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide ^[4] .

In Vitro

Pterostilbene (0, 5, 25, 50, 100, 200 and 400 µM) shows inhibitory activity against the growth of HeLa cells, with IC ₅₀ s of 101.2 µM and 65.9 µM at 24 and 48 hrs, respectively. Ipterostilbene (0, 25, 100 and 200 µM) also induces the apoptosis HeLa cells ^[2] .
Pterostilbene (0.05, 0.1, 0.15 and 0.2 mM) has high anti-oxidant activity against DPPH, ABTS, hydroxyl, superoxide, hydrogen peroxide in a dose-dependent manner. Pterostilbene decreases lipid peroxides and hydroperoxides, reduces protein carbonyl groups and restores protein sulphydryl groups in response to damage by TBHP and As-Fe ²⁺ . Pterostilbene also inhibits single strand breaks in pBR322 ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pterostilbene (30 mg/kg daily, p.o. for 21 days) inhibits reactive oxygen species production in the animal model of inflammation ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03635411	Elysium Health\|University of Pennsylvania	Recovery of Function	December 6, 2018	Phase 1
NCT03671811	City of Hope Medical Center\|National Cancer Institute (NCI)	Atypical Endometrial Hyperplasia\|Endometrial Carcinoma	January 21, 2019	Phase 2
NCT01267227	University of Mississippi Medical Center	Hyperlipidemia\|Blood Pressure\|Oxidative Stress	December 2010	Phase 2\|Phase 3
NCT04342975	Mayo Clinic\|Elysium Health	AKI	December 1, 2020	Phase 2
NCT05561075	Fundació Eurecat\|Circe, S.L.	Biological Availability	October 2022	Not Applicable

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 110 mg/mL ( 429.18 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9017 mL	19.5084 mL	39.0168 mL
5 mM	0.7803 mL	3.9017 mL	7.8034 mL
10 mM	0.3902 mL	1.9508 mL	3.9017 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3.93 mg/mL (15.33 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.75 mg/mL (10.73 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.75 mg/mL (10.73 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Phenol, 4-[(1E)-2-(3,5-dimethoxyphenyl)ethenyl]-

4-Stilbenol, 3′,5′-dimethoxy-, (E)-

Phenol, 4-[2-(3,5-dimethoxyphenyl)ethenyl]-, (E)-

4-[(1E)-2-(3,5-Dimethoxyphenyl)ethenyl]phenol

Pterostilbene

3,5-Dimethoxy-4′-hydroxy-trans-stilbene

trans-3,5-Dimethoxy-4′-hydroxystilbene

trans-Pterostilbene

(E)-2-(3,5-Dimethoxyphenyl)-1-(4-hydroxyphenyl)ethene

(E)-4-Hydroxy-3′,5′-dimethoxystilbene

(E)-4-(3,5-Dimethoxystyryl)phenol

E-Pterostilbene

P 1499